

HPAP-092 Donor Summary



HPAP	092	UNOS		
Recovery OPO	One Legacy	Allocation Via	UPENN <input type="checkbox"/> nPOD <input checked="" type="checkbox"/>	
Age (years)	21	DCD	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>	
Race	Hispanic	DBD	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>	
Sex	M <input checked="" type="checkbox"/> F <input type="checkbox"/>	Admission to Cross Clamp	144 Hours 16 Min	
ABO (Rh)	A+	Cross Clamp Time	4/16/2021 17:01 EST	
BMI (Kg/m²)	25.59	Cold Ischemia Time*	18 Hours 33 Mins.	
Weight (kg)	82.20			
Height (cm)	179.07			
Cause of Death	Head Trauma	Preservation Solution	UW <input checked="" type="checkbox"/> HTK <input type="checkbox"/>	
Mechanism of Injury	Gunshot Wound	Organs Recovered	Heart <input type="checkbox"/> Kidney <input checked="" type="checkbox"/> Lung <input type="checkbox"/> Pancreas <input checked="" type="checkbox"/> Liver <input checked="" type="checkbox"/> Intestine <input type="checkbox"/>	
Cardiac Arrest/Downtime	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> Unknown duration	Intraoperative time lapse from liver to pancreas removal from the peritoneal cavity:	Hours Mins. N/A	
CPR / Time	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	Organs Discarded	Heart <input type="checkbox"/> Kidney <input type="checkbox"/> Lung <input type="checkbox"/> Pancreas <input type="checkbox"/> Liver <input type="checkbox"/> Intestine <input type="checkbox"/>	
Total Est. Downtime	Unknown duration	Blood Culture	No Growth	
Date /Time of Admission	4/10/2021 13:45 PDT 4/10/2021 16:45 EST	PHS High Risk	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>	
		Acute Lung Injury	Minimal atelectasis at the left costophrenic angle	

*Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.

HPAP-092 Donor Summary



Medical History:

		Duration	Medications	Compliance
Type of Diabetes	None	----	----	----
History of cancer	----	----	----	----
CAD	----	----	----	----
Hypertension	----	----	----	----
Hyperlipidemia	NA	NA	----	----
Autoimmune disease	NA	NA	----	----
Family History	CAD <input type="checkbox"/>	Diabetes <input type="checkbox"/>	Auto immune disease <input type="checkbox"/>	Others:
Surgical History:	L sided chest tube placed in 2015 patient born with a cataract to right eye, cataract placed lens in 2001			
Comments:	Took an unknown growth hormone in 2010.			

Hemodynamic Profile

Average BP During Hospitalization (mmHg)	133/80	
Average Low BP During Hospitalization	NA	Duration: NA
Average BP in OR (mmHg)	NA	
Average Low BP in OR (mmHg)	NA	Duration: NA
Average HR in OR (bpm)	NA	
ABG-pH range	7.07 - 7.53	

INTERVENTION

Blood Products/Meds Transfused Before Organ Recovery

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	215-326	3	764
PRBCs	325 - 500	6	2300
Platelets	271	1	271
Norepinephrine (Levophed)	----	2.00 mcg/min(one dose) started on 4/10/21	
Vasopressin	----	0.18– 2.4 units/hrs. started on 4/10/21 DC'd on 4/14/21 for the duration of >5 hrs.	
Neo-Syneprine	----	----	----
Epinephrine	----	----	----
Phenylephrine	----	----	----
Dopamine	----	----	----

HPAP-092 Donor Summary



Blood Products/Meds Transfused Intraoperative

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	NA	NA	NA
PRBCs	NA	NA	NA
Platelets	NA	NA	NA
Norepinephrine (Levophed)	NA	NA	NA
Vasopressin	NA	NA	NA
Neo-Syneprine (phenylephrine)	NA	NA	NA
Epinephrine	NA	NA	NA
Dopamine	NA	NA	NA
Heparin	NA	NA	NA

Initial Autoantibody Screening (nPOD): ELISA

GAD-65	IA-2
Positive	Negative

Confirmatory results: Radioimmuno Assay (RIA)

	GAD-65 (unit/ml)	IA-2 (unit/ml)	Insulin AAB (unit/ml)	ZnT8 (unit/ml)
Results: Recovery	0	0	0.001	-0.004
Results: screening	38	0	-0.001	-0.003
Cut-off values	20	5	0.010	0.020

*Sample obtained at time of organ recovery.

	C-peptide (ng/ml)	Proinsulin
Results	15.35	NA

*Sample obtained at time of organ recovery.

HLA (OPO)*

Class 1	A	2	24	Class II	DR	4	4
	B	35	35		DR51	N-Negative	----
	C	04	04		DR52	N-Negative	----
	Bw4	Negative			DR53	53	----
	Bw6	Positive			DQB1	7	8
			DQA1		03	03	
			DPB1		04:01	04:01	
Comment:							

HPAP-092 Donor Summary



Confirmatory HLA (UPENN)*

Class 1	A	02:01	24:02	Class II	DRB1	04:02	04:08
	B	35:01	35:03		DRB3	----	----
	C	04:01	----		DRB4	01:03	----
					DRB5	----	----
					DQB1	03:01	03:02
					DQA1	03:01	03:03
					DPB1	04:01	----
					DPA1	01:03	----

*HLA typing performed using NGS

Infectious Disease Serology

Test	Result	Hemo/Plasma Dilution Status	
		Qualified	Non-Qualified
EBV IgG	Positive	✓	-
EBV IgM	Negative	✓	-
CMV	Negative	✓	-
HBcAb	Negative	✓	-
HBsAg	Negative	✓	-
HCV Ab	Negative	✓	-
HIV I/II	Negative	✓	-
Syphilis	Negative	✓	-
Procleix Ultrio	ND	----	----
Ultrio HBV	Negative	✓	-
Ultrio HCV	Negative	✓	-
Ultrio HIV	Negative	✓	-
Toxoplasma Ab	Negative	✓	-
SARS-CoV-2	Positive	✓	-

HPAP-092 Donor Summary



Laboratory Panel

	Initial	Peak	Terminal
Na (mEq/L) (135-145)	136	148	137
Creatinine (<1.5)	0.91	9.68	2.90
Glucose (mg/dL) (60-150)	237	237	140
HbA1C%	5.6	----	----
Total bilirubin (0-1.0)	0.6	2.6	2.2
SGOT (AST) (0-40)	78	293	37
SGPT (ALT) (5-35)	49	326	129
Alkaline phosphatase (45-110)	55	55	39
Serum Amylase (23-851)	377	428	265
Serum Lipase (0-80)	78	95	95
WBC (THO/uL) (4.5-11.0)	10.5	23.7	14.2
Hgb (g/dL) (12-16)	14.8	14.8	9.0
Platelets (THO/uL) (150-350)	165	165	55
INR (<2.0)	2.00	2.00	1.20

Urinalysis

	1 st	2 nd	3 rd	4 th
Glucose	Negative	----	----	-----

Medications During Hospitalization

Steroids**	Solumedrol 500 mg started on 4/12/21		
Diuretics	Lasix 160.00 mg/66 ml 4/13/21 9:00		
T3 Protocol	-----		
T4 Protocol*	-----		
Insulin**	5-7 units /hr started on 4/13/21 DC'd on 4/10/21 15:19		
Antihypertensive	Labetalol 10-20 mg started on 4/13/21		
Vasodilators	-----		
DDAVP**	-----		
Total parenteral nutrition	-----		
Other	levothyroxine 15-20 mcg, pepcide, Ceftriaxone, Thiamine, Zosyn 3.37gr, vancocin 750 mg, Dobutamine 0.25 mcg/kg,	Specify	

*T4 protocol: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015:7 17-27.

** Excluding T4 Protocol